Attention-deficit/hyperactivity disorder (ADHD) is characterized
|
|
- Dwayne Malone
- 5 years ago
- Views:
Transcription
1 THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION Treatment of Adults With Attention-Deficit/Hyperactivity Disorder David A. Baron, DO, MSEd Michele T. Pato, MD Rebecca L. Cyr, BA Attention-deficit/hyperactivity disorder (ADHD) is a clinically important neuropsychiatric developmental disorder that affects children, adolescents, and adults. The disorder is characterized by core symptoms of inattention, hyperactivity, distractibility, impulsivity, and impaired executive functioning. It is estimated that 2% to 5% of the adult population in the United States has ADHD. Adults with ADHD are at an increased risk for experiencing comorbid psychiatric disorders, including mood disorders, anxiety disorders, and substance use disorders. The authors provide a brief clinical overview of ADHD and the treatment of adults with this disorder. J Am Osteopath Assoc. 2011;111(11): From the Department of Psychiatry and Behavioral Sciences at Keck School of Medicine of the University of Southern California in Los Angeles. Financial Disclosures: None reported. Address correspondence to Rebecca L. Cyr, BA, Special Projects Manager, Department of Psychiatry and Behavioral Sciences, Keck School of Medicine of the University of Southern California, 2250 Alcazar St, CSC 2200, Los Angeles, CA rcyr@usc.edu Submitted March 22, 2011; final revision received June 30, 2011; accepted July 15, JAOA Vol 111 No 11 November 2011 Attention-deficit/hyperactivity disorder (ADHD) is characterized by core symptoms of inattention, hyperactivity, distractibility, and impulsivity. 1 Unlike most other psychopathologic conditions, which were originally thought to occur only in adults, ADHD was initially believed to affect only children and adolescents. Sir George Frederic Still, MD, the proclaimed father of British pediatrics, provided the first clinical description of ADHD in a series of 3 lectures given to the Royal College of Physicians in London in From then until the mid-1970s, when Wood et al 3 first described ADHD in adults, ADHD was thought to be psychic acne that an individual grew out of over time. In reality, more than 50% of children with ADHD will carry the disorder into adulthood. The initial lack of recognition that an adult form of ADHD exists can be attributed to the fact that many of the presenting symptoms seen in children morph over time (Figure 1). 4,5 An adult with ADHD is not likely to run around erratically in his or her place of work or in social settings. Instead, that person may feel restless and have a difficult time sitting still and maintaining focus. Children typically have parents and teachers to help organize their lives, but adults typically do not. Thus, common dysfunctions of adults with ADHD include their inability to organize their lives, meet deadlines, avoid impulsive behavior, and attend to boring tasks. 6 The life consequences resulting from these deficits can be devastating for patients and their families. Although the behaviors observed in children with ADHD may appear to change as they grow into adults, the core symptoms of inattention, impulsivity, and distractibility are relatively constant over time unlike symptoms of mood and anxiety disorders, which are episodic and can wax and wane. The continuous nature of ADHD symptoms helps to explain why most adults with the disorder never receive a diagnosis or treatment. It s just who I am and always have been, is a common explanation of patients with lifelong core symptoms. It is often a comorbid mood or anxiety disorder that causes an individual with ADHD to seek treatment. Attention-deficit/hyperactivity disorder responds to pharmacotherapy and behavioral therapy, particularly cognitive
2 KEY POINTS ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) affects people of all ages and IQ levels. DEFICITS OF EXECUTIVE FUNCTIONING CAN MAKE IT difficult for people to function at full capacity in academic, occupational, and social environments and in other activities of daily living. COMORBIDITY IS COMMON IN ADULTS WITH ADHD. CONSIDER A DIAGNOSIS OF ADHD IN PATIENTS presenting with any of the core symptoms (ie, distractibility, hyperactivity, impulsivity, inattention), substance abuse, and mood/anxiety disorders, as well as in patients with a long history of psychosocial dysfunction. CLOSELY MONITOR PHARMACOLOGIC TREATMENTS. LONG-ACTING/EXTENDED-RELEASE STIMULANTS OR nonstimulants are effective first-line treatments; shortacting stimulants should be avoided for adults with ADHD. NONPHARMACOLOGIC TREATMENTS, INCLUDING cognitive behavioral therapy and time-management training, should be considered for all adults with ADHD. behavioral therapy. According to a 2009 meta-analysis, 7 recent clinical reports have suggested that neurofeedback, an advanced form of biofeedback, may be effective in treating adults and children with ADHD. To our knowledge, randomized controlled clinical trials have not been highlighted in top tier peer-reviewed journals to date. Some patients report receiving benefits from life coaches who are specifically trained to assist adults with ADHD. 8 Regardless of the treatment modality selected, it is well established that untreated adults with ADHD score below average on measures of overall mental health, compared with matched adults without ADHD. In addition to the core symptoms of inattention, distractibility, impulsivity, and hyperactivity, an important area of clinical assessment when evaluating adults with ADHD should be executive functioning. 9 Executive Functioning According to the age-of-onset criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), individuals diagnosed as having ADHD must present with clinically impairing symptoms by age 7 years (Figure 2). 10 In actual clinical settings, however, many patients with ADHD first present for treatment in adulthood. 11,12 Faraone et al 11 question the DSM-IV age-of-onset criteria, arguing that the age is set too low. They assert that the diagnostic criteria should be revised to include patients whose condition was first diagnosed in adolescence. The key diagnostic feature is evidence of core ADHD symptoms before adulthood, even if the diagnosis was never made in childhood or early adolescence. It is now estimated that at least 4% of the adult population in the United States may have symptoms of ADHD. 13 Compared to matched individuals without ADHD, untreated patients with ADHD face serious disabilities and morbidities, including lower education levels, poorer employment records, and more partner separation and divorce. 13,14 Many of these adverse life outcomes are directly related to difficulties with executive functioning. According to Brown et al, 15 adults with ADHD experience difficulties with executive functioning on a daily basis, particularly in the areas of organizing one s routine tasks, working within deadlines, making consistent efforts, remembering, and maintaining adequate focus. To measure core executive functioning deficits in adults with ADHD, Brown 16 developed a rating scale, known as the Brown Attention Deficit Disorder (ADD) Scale for Adults. He described these deficits as being related to the following 5 core areas of executive functioning: activation, focus, effort, emotion, and memory. Barkley et al 9 expanded this concept, noting that expression of symptoms in these 5 areas can include distractibility, impulsiveness, poor concentration, lack of persistence, problems with working memory, and poor organizational skills. Biederman et al 14 performed an extensive evaluation of executive functioning in adults, focusing on measurements that were sensitive to detecting problems with sustained attention/vigilance, planning and organization, response inhibition, set shifting and categorization, selective attention and visual scanning, verbal and visual learning, and memory. The researchers tests were used to compare these areas of executive functioning among the following 4 groups of adults: adults with ADHD who did not have executive functioning problems adults with both ADHD and executive functioning problems Children Motoric hyperactivity Aggressiveness Low frustration tolerance Impulsiveness Adults Easily distracted Inattentiveness Shifts activities Easily bored Impatience Restlessness Figure 1. Developmental trends in symptoms of attention-deficit/hyperactivity disorder from childhood to adulthood. Adapted from Wilens et al 4 and Millstein et al. 5 JAOA Vol 111 No 11 November
3 Persistent pattern of inattention and/or hyperactivityimpulsivity Symptoms must be present for past 6 months Must have 6 or more symptoms of inattention and/or hyperactivity-impulsivity Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 years Some impairment from symptoms must be present in 2 or more settings (eg, at home and at school or work) Clinically significant social, academic, or occupational impairment Symptoms not exclusively caused or better accounted for by another mental disorder Figure 2. Diagnostic criteria for attention-deficit/hyperactivity disorder. Adapted from the American Psychiatric Association s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). 10 adults without ADHD but with executive functioning problems adults with neither ADHD nor executive functioning problems Adults with both ADHD and executive functioning problems performed the worst in all measurements, and adults with neither ADHD nor executive functioning problems performed the best. In an analysis of the number of traffic tickets, traffic accidents, and arrest records of the study participants, the 2 groups with ADHD despite differences in executive Until the mid-1970s, ADHD was thought to be psychic acne that an individual grew out of over time. functioning were found to have received more traffic tickets, been involved in more traffic accidents, and been arrested more often than those without ADHD. 14 Interestingly, subtle deficits in executive functioning can affect adults with ADHD independently of intellectual capacity. Brown et al 15 studied the relationship between individuals IQ and executive functioning. The study sample included individuals who had ADHD and an IQ higher than 120, representing a group that was 1.5 standard deviations above the general population s mean IQ of 100. Eight measures of executive functioning were assessed, and the ADD Scale for Adults was administered. The study population consisted of 157 adults between ages 18 and 55 years. Analysis of the data revealed that more than 70% of the patients reported statistically significant impairment in 4 of the 5 core areas of executive functioning (activation, focus, effort, and memory). Overall, 73% of the patients reported statistically significant impairment in at least 5 of 8 additional executive functioning measures. Of note, patients with ADHD who had higher IQ scores were more functionally impaired than patients without ADHD who had lower IQ scores. 15 These reported observations on executive functioning underscore the importance of establishing an accurate diagnosis and developing an effective treatment strategy. An important research finding is that having a high IQ does not preclude an individual from having ADHD. In fact, deficits in executive functioning may be more disabling in adult patients with high IQs. Adults with high IQs even if they found ways of adapting to ADHD in childhood are often frustrated by underachievement in school and work settings, knowing that their performance does not live up to their potential. 15,17 With adequate treatment, however, life goals can be achieved or exceeded. 18 General Treatment Guidelines A Google search of treatment of adult ADHD on November 4, 2011, yielded more than 3 million results. The Internet has become a primary source of health information for patients worldwide. This development is a double-edged sword. The Internet allows easy access to some credible, evidence-based information on health. However, not all Internet content is peer reviewed, making it difficult for the public to distinguish between genuine science vs personal opinions and marketing strategies. As treating physicians, we must consider it vital to educate our patients about ADHD. Effective treatment starts with an accurate diagnosis. Although a number of excellent, valid, and reliable symptom screening techniques and diagnostic psychometric tools are available to assist physicians, an accurate diagnosis is dependent on a comprehensive interview with the patient conducted by a provider who is knowledgeable about ADHD. Extensive, and usually expensive, psychological testing is not necessary. Attaining corroborating information on patient history from family members is important to establish an accurate diagnosis. It is disappointing that, despite increased awareness among physicians that ADHD can persist into adulthood, only about 11% of adults with ADHD have received treatment. 13 After confirmation of a diagnosis of ADHD, including any comorbid psychopathologic conditions, appropriate medication therapy (Figure 3) 19 and psychotherapy should be initiated. Long-acting stimulant medications are the most widely prescribed pharmacologic treatment for patients with ADHD and are generally the first drugs of choice for adult patients. Because of the potential for abuse and the need for multiple daily dosing, short-acting stimulant medications should be 612 JAOA Vol 111 No 11 November 2011
4 Recommended Dosing Ranges Medication Proprietary Name for Adults, mg/d Long-Acting/Extended-Release Stimulants Amphetamine sulfate Adderall XR (Shire US; Wayne, PA) Dexedrine Spansule (Amedra 5-60 Pharmaceuticals; Middlesex, NJ) Vyvanse (Shire US; Wayne, PA) Methylphenidate Concerta (Janssen Pharmaceuticals; hydrochloride Titusville, NJ) Focalin XR (Novartis Pharmaceuticals; Metadate CD (UCB; Smyrna, GA) Methylin ER (Shionogi USA; Florham Park, NJ) Ritalin LA (Novartis Pharmaceuticals; Ritalin SR (Novartis Pharmaceuticals; Nonstimulants Atomoxetine hydrochloride Strattera (Eli Lilly and Co; Indianapolis, IN) Guanfacine hydrochloride Intuniv (Shire US; Wayne, PA) 1-4 used only rarely in treating adults with ADHD. For all adolescent and adult patients receiving stimulants, issues related to nonmedical use, diversion, substance abuse, and dependence should be monitored on an ongoing basis. Atomoxetine hydrochloride is a nonstimulant medication approved by the US Food and Drug Administration (FDA) for the management of ADHD in adults. 20 This drug may be particularly effective in patients with comorbid anxiety, tics, or a history of drug abuse. 21 As a nonstimulant, atomoxetine prescriptions can be renewed over the phone, allowing clinically stable patients to receive multiple refills. For patients with contraindications (eg, high abuse liability, medical conditions, known hypersensitivity), a nonstimulant should be considered. 22 When initiating pharmacotherapy, it is important for physicians to inform patients about what to expect from treatment. Clinical concerns such as decreased appetite, possible sleep problems, headache, and increased heart rate should be reviewed with patients. Patients who have a personal or family history of cardiac disease, who report passing out while exercising, or who have cardiac murmur should be screened for baseline disease, including untreated hypertension, arrhythmias, and structural cardiac defects. To our knowledge, no data exist to warrant serial electrocardiogram monitoring in otherwise heart-healthy individuals. 23 Psychotherapeutic intervention (ie, talk therapy ) is often an important component of treatment for adults with ADHD. Cognitive behavioral therapy for managing problems of focus, organization, motivation, and memory as they Figure 3. Medications used, with available proprietary brands and dosing ranges, for the treatment of adults with attentiondeficit/hyperactivity disorder. Adapted from Physicians Desk Reference (http: // relate to executive functioning has been found to be successful in adults. 11 Given the high occurrence of comorbid psychopathologic conditions in adults with ADHD, 13,22,24 a comprehensive treatment strategy is typically required. In a 2004 study, Biederman 24 found that both men and women with ADHD had much higher lifetime prevalence of major depression (27% and 36%, respectively), compared with male and female controls (4% and 6%, respectively). Similarly, Biederman 24 found that men and women with ADHD had higher lifetime prevalence of multiple (>2) anxiety disorders (46% and 52%, respectively), compared with male and female controls (10% and 15%, respectively). When comorbid conditions are present, pharmacologic treatment and psychotherapy aimed at all co-occurring disorders is important. Multiple medications may be required to achieve maximal clinical benefit. 8 Finally, all treatment strategies should be patient-centered and based on the concept of personalized medicine. For adults with ADHD, lifestyle changes should always be considered in patient care. An initial assessment of the patient for any unique lifestyle dysfunction is important. For example, an Only about 11% of adults with ADHD have received treatment. adult may be struggling in a job that requires intense concentration and attention to detail, but that same individual may enjoy success in a position that allows for less attention to detail and an emphasis on big-picture skills. Treatment should address all problematic areas, including interpersonal relationships, occupational issues, self-esteem, and social functioning. Issues related to a lifelong history of feeling like an underachiever may need to be addressed in the patient with ADHD. 18 Appropriate treatment for ADHD can positively impact a patient s marriage, job, and overall selfesteem and life functioning. JAOA Vol 111 No 11 November
5 Recommended Reading A useful book on this subject is Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, by Russell A. Barkley, PhD (3rd ed, New York, NY, Guilford Press, 2005). In the book, Dr Barkley stresses differences in diagnosis and treatment between children, adolescents, and adults. Conclusion Recent epidemiologic studies report at least 4% of the adult population in the United States may have ADHD. A crucial area of clinical assessment when evaluating adults with ADHD is executive functioning. Serious life disturbances, such as relationship and occupational problems, resulting from dysfunction in executive functioning underscore the importance of establishing an accurate diagnosis and developing an effective treatment strategy for patients with ADHD. Adults with ADHD respond well to pharmacotherapy and behavioral therapy, particularly cognitive behavioral therapy (eg, managing problems of focus, organization, motivation, and memory). Short-acting stimulants should be avoided in treating adults with ADHD. Lifestyle changes should be a consideration in treatment. References 1. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attentiondeficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18(3): Still GF. The Goulstonian lectures on some abnormal psychical conditions in children. Lancet. 1902;159: Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12): Wilens TE, Biederman J, Spencer TJ. Attention-deficit/hyperactivity disorder in youth. In: Hendren RL, ed. Disruptive Behavior Disorders in Children and Adolescents. Arlington, VA: American Psychiatric Publishing; Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Attention Disord. 1997;2(3): McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162(9): Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci. 2009;40(3): Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: Guilford Press; Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000: Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163(10): Faraone SV, Antshel KM. Diagnosing and treating attention-deficit/hyperactivity disorder in adults. World Psychiatry. 2008;7(3): Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4): Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10): Brown TE, Reichel PC, Quinlan DM. Executive function impairments in high IQ adults with ADHD [published online ahead of print May 6, 2009]. J Atten Disord. 2009;13(2): Brown TE. Brown Attention-Deficit Disorder Scales for Adolescents and Adults. San Antonio, TX: Psychological Corporation; Antshel KM, Faraone SV, Maglione K, et al. Executive functioning in high-iq adults with ADHD. Psychol Med. 2010;40(11): Baron DA. The gold medal face of ADHD. J Atten Disord. 2010;13(4): Physicians Desk Reference. 64th ed. Montvale, NJ: PDR Network LLC; Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD [published online ahead of print December 21, 2009]. J Atten Disord. 2011;15(2): Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? a meta-analytic review of the literature. Pediatrics. 2003;111(1): Baron DA, Bizamcer AN. The relationship of ADHD, its treatment, and substance use. Behav Health Manage. 2004;24(4):S1-S Otto MA. Sudden death risk with ADHD stimulants is low: if answer to four questions is yes, don t hesitate to enlist help of a pediatric cardiologist. Clinical Psychiatry News. 2011;39(2): Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(suppl 3):3-7. JAOA Online Archives Archives of JAOA The Journal of the American Osteopathic Association content as far back as 1950 are available online at Beginning with the January 2000 issue, JAOA articles, letters, and other contributions are available in full text, PDF documents, or both. In addition, members of the American Osteopathic Association and JAOA subscribers can access content from the past 12 months free of charge. 614 JAOA Vol 111 No 11 November 2011
QUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationPsychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.
Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence
More informationWhat are the most common signs of ADHD? And what are the most common medication interventions?
What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina
More informationThe Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
More informationAttention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.
Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. PREVALENCE & STATISTICS 6-8% of all children have ADHD (CDC Statistical Data) Age of onset: 7 years old (Prior DSM-IV) 12 years old (Current
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationAbout AD/HD. American Osteopathic College of Occupational and Preventive Medicine 2015 Mid Year Educational Conference, Ft Lauderdale, Florida J-1
Adolescent and Adult ADHD: An Update on Impact, Diagnosis and Treatment Joel L. Young, M.D. Medical Director: Rochester Center for Behavioral Medicine Teaching Faculty: Wayne State University School of
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
More informationMANAGEMENT OF ADHD IN ADULTS
MANAGEMENT OF ADHD IN ADULTS RICHARD MOLDAWSKY, M.D. I Can t Focus on Anything Except Getting My Adderall 1 ASSUMPTIONS FOR TODAY Most of us don t work 2 W s without seeing a person with ADHD You are familiar
More informationDriving to Distraction
Driving to Distraction New Research on the Impact of ADHD and ADHD Medications on Driving performance Daniel J. Cox, Ph.D., A.B.P.P Professor, Departments of Psychiatric and Internal Medicine Director,
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationAsk The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
More informationFor more than 100 years, extremely hyperactive
8 W H A T W E K N O W AD/HD Predominantly Inattentive Type For more than 100 years, extremely hyperactive children have been recognized as having behavioral problems. In the 1970s, doctors recognized that
More informationIndividuals wishing to seek an evaluation for ADHD
9 WHAT WE KNOW Diagnosis of ADHD in Adults Individuals wishing to seek an evaluation for ADHD should use this information and resource sheet as a set of guidelines for what to expect from the clinician
More informationUpdate on the Treatment of ADHD 2019
Update on the Treatment of ADHD 2019 James H. Beard, Jr., M.D, FAAP Developmental-Behavioral Pediatrician Division of Developmental Pediatrics The Rights of ADHD The right diagnosis of ADHD and co morbidities
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More
More informationComorbidity With Substance Abuse P a g e 1
Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric
More informationPresented by the National Resource Center on ADHD
Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationTOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD)
TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD) TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) The clinical tool kit is intended
More informationPharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants
AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic
More informationObjectives. What is ADHD? Introduction to Adult ADHD
Introduction to Adult ADHD Virginia Newton, Ph.D., R.Psych. Brentwood Psychological Services www.brentwoodpsych.com (780) 232-2489 August 15, 2018 11 Objectives Learn the differences between childhood
More informationThe shift in nosology from the Diagnostic PROCEEDINGS FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT
FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) tends to manifest differently in adolescents than in children,
More information2013 Virtual AD/HD Conference 1
Medication for ADHD & Coexisting Conditions Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com www.adhdpodcast.com
More informationCitation for published version (APA): Jónsdóttir, S. (2006). ADHD and its relationship to comorbidity and gender. s.n.
University of Groningen ADHD and its relationship to comorbidity and gender Jónsdóttir, Sólveig IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationAttention Deficit Hyperactivity Disorder Overview and New Perspectives
1st Annual Regional Psychiatry Conference Psychiatry for the Non-Psychiatrist Attention Deficit Hyperactivity Disorder Overview and New Perspectives Thomas B. Henry, MD Board Certified Child & Adolescent
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationIs ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD
Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationEFFECTS OF ADHD ON EARLY LEARNING AND ACDEMIC PERFORMANCE 1
EFFECTS OF ADHD ON EARLY LEARNING AND ACDEMIC PERFORMANCE 1 The Effects of ADHD on Learning and Academic Performance in the Pre- and Elementary School Years. Christopher Kalogeropoulos November 19, 2012
More informationPharmacotherapy of ADHD Across the Lifecycle: Stimulants
Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Percent Change (Bmax/Kd) DVR Images Obtained with [ 11 C]Raclopride
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationPharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationTRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Sue Duvall, RN, MPA Associate Director, Drug Regulatory Affairs Pharmaceuticals
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationCould I Have Attention-Deficit/ Hyperactivity Disorder (ADHD)?
Could I Have Attention-Deficit/ Hyperactivity Disorder (ADHD)? Finding an Answer to ADHD as an Adult Do you feel that you have struggled throughout your life with poor concentration, inattention, impulsivity,
More informationDr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for
Dr S H Jawed Syed.Jawed@dwmh.nhs.uk 01922607039 Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Adult Neurodevelopmental Service, DWMHP NHS Trust Regional
More informationCurrent Research on the Effective Treatment of. Attention-Deficit/Hyperactivity Disorder. Carolyn Micheli
ADHD Treatment 1 RUNNING HEAD: ADHD Treatment Current Research on the Effective Treatment of Attention-Deficit/Hyperactivity Disorder Carolyn Micheli ADHD Treatment 2 Abstract This paper will explore Attention-Deficit/Hyperactivity
More informationDoes prescribing stimulants to patients with attention-deficit/hyperactivity
Do stimulants for ADHD increase the risk of substance use disorders? For some patients, stimulants might protect against future SUDs Shailesh Jain, MD, MPH, ABDA Regional Chair Associate Professor Department
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationAD/HD Across the Lifespan. Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida.
AD/HD Across the Lifespan Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida. Worldwide Prevalence of ADHD Is 3% to 7% Studies of ADHD prevalence United
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationIndividuals with attention-deficit/hyperactivity
3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or
More informationEffectively Recognizing and Managing ADHD in Adolescents. Educational Objectives
Educational Objectives After completing this activity, the participant should be better able to: Explain how the proper recognition and management of ADHD in adolescents by MCOs can improve clinical outcomes
More informationADHD and Substance Use Disorders: An Intoxicating Combination
ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital
More informationDrug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
More informationAbout ADHD. National Resource Center on ADHD A Program of CHADD
About ADHD Everybody can have difficulty sitting still, paying attention or controlling impulsive behavior once in a while. For some people, however, the problems are so pervasive and persistent that they
More informationTrouble shooting medication adjustment and side effect management in children with ADHD
Trouble shooting medication adjustment and side effect management in children with ADHD Drs. Joanna Holland and Sarah Manos 44 th Annual Dalhousie Spring Refresher April 5, 2018 Disclosure We have no disclosures
More informationORIGINAL INVESTIGATION. Attention-Deficit/Hyperactivity Disorder in Adults. A Survey of Current Practice in Psychiatry and Primary Care
ORIGINAL INVESTIGATION Attention-Deficit/Hyperactivity Disorder in Adults A Survey of Current Practice in Psychiatry and Primary Care Stephen V. Faraone, PhD; Thomas J. Spencer, MD; C. Brendan Montano,
More informationADHD Training for General Practitioners
ADHD Training for General Practitioners Learning Objectives Understand the stigma surrounding ADHD and develop ability to challenge stigma. Understand your role in the ADHD pathway. Understand what you
More informationIs ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD
Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric
More informationWeek 2: Disorders of Childhood
Week 2: Disorders of Childhood What are neurodevelopmental disorders? A group of conditions with onset in the developmental period Disorders of the brain The disorders manifest early in development, often
More informationPresented by the. National Resource Center on ADHD
Presented by the National Resource Center on ADHD www.help4adhd.org (800) 233-4050 Daniel Cox, PhD Director of the Virginia Driving Safety Laboratory Professor of Psychiatric & Internal Medicine, University
More informationTitle: ADHD: Symptom Reduction in Follow up Period CMS ID: PP3 NQF #: N/A
Source(s) Office of the National Coordinator for Health Information Technology/Centers for Medicare & Medicaid Services Measure Domain Effective Clinical Care: Outcome Brief Abstract Description Percentage
More informationstudied and the number of sources used to establish a diagnosis (home, school, clinics, etc.). The absence of laboratory tests or neuroimaging
LEND Brief Attention deficit hyperactivity disorder Fall 2013 1 LEND Brief Attention Deficit Hyperactivity Disorder Fall 2013 INTRODUCTION By Michael I. Reiff, MD, FAPP & Martin T. Stein, MD, FAPP Overactive
More informationAdult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines
Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines Umesh Jain B.Sc., M.D., F.R.C.P.(C), D.A.B.P.N., Ph.D., M.Ed. (Cand.) Hospital for Sick Children /Centre for Addiction and
More informationDEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES
DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES Scott R. Smith, MD, MPH Developmental-Behavioral Pediatrician University of Rochester Medical Center Common Complaints about Children with Problems Your
More informationAttention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy
Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy Questions from chapter 1 1) For a diagnosis of ADHD, some symptoms that cause impairment must be present before
More informationUnderstanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD
Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD Dr. Don Duncan Clinical Director BC Interior ADHD Clinic Kelowna, BC Mental Health Summit Vancouver, BC December
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationF O C A L I N P R O D U C T M O N O G R A P H C H NO HCl
FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl CONTENTS Introduction..........................................................................1 Background of
More informationPage: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
More informationOVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationConsolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults
FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationADHD: MORE THAN ATTENTION PROBLEM JULIE STECK, PH.D., HSPP CRG/CHILDREN S RESOURCE GROUP
ADHD: MORE THAN ATTENTION PROBLEM JULIE STECK, PH.D., HSPP CRG/CHILDREN S RESOURCE GROUP WWW.CHILDRENSRESOURCEGROUP.COM UNDERSTANDING THE NATURE OF ADHD IS CRITICAL TO TREATING THE DISORDER HYPERACTIVITY
More informationPRESCRIBING PHYSICIANS PLEASE READ
PRESCRIBING PHYSICIANS PLEASE READ USADA s mission is to protect the rights of clean athletes. Some athletes need to use stimulants to manage ADD/ADHD and the anti-doping community acknowledges and respects
More informationMethylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
More informationContents Definition and History of ADHD Causative Factors
1 Definition and History of ADHD................... 1 Brain Damage Syndromes........................ 1 Alternative Terms for ADHD...................... 2 Evolution of Present Concept of ADHD................
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationExecutive Functions and ADHD
Image by Photographer s Name (Credit in black type) or Image by Photographer s Name (Credit in white type) Executive Functions and ADHD: Theory Underlying the New Brown Executive Functions/Attention Scales
More informationPAL Conference Cle Elum March 2015
Source Research Funding Books, Intellectual Property Advisor/ Consultant Speakers Bureau Employee In-kind Services (example: travel) Stock or Equity Honorarium or expenses for this presentation or meeting
More informationAdult ADHD for GPs. Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD
Adult ADHD for GPs Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD I m a Believer.. Are You? What is ADHD? ADHD is a valid clinical condition defined
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
More informationOH, Adolescents and Attention Deficit Hyperactivity Disorder (ADHD) How do you deal with them? Presented By: Todd Twogood MD, FAAP
OH, Adolescents and Attention Deficit Hyperactivity Disorder (ADHD) How do you deal with them? Presented By: Todd Twogood MD, FAAP Teenagers Time of Transformation Allergy to Parents The Real Self Looks
More informationADHD and Comorbid Conditions A Conceptual Model
ADHD and Comorbid Conditions A Conceptual Model Thomas E. Brown PhD. Assistant Clinical Professor of Psychiatry, Yale University School of Medicine and Associate Director of the Yale Clinic for Attention
More informationThe relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications
Society for the Study of Addiction, York The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications November 12.th 2010 Soren Dalsgaard, MD, PhD, associate
More informationAttention Deficit Hyperactivity Disorder in Children and Adults
Attention Deficit Hyperactivity Disorder in Children and Adults Steven R. Pliszka, MD Professor and Chair Department of Psychiatry The University of Texas Health Science Center at San Antonio Speaker Disclosure
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationAttention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD
Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must
More informationUNIVERSITY OF WISCONSIN LA CROSSE. The ACCESS Center
UNIVERSITY OF WISCONSIN LA CROSSE 165 Murphy Library 1725 State Street La Crosse, WI 54601 Phone: (608) 785-6900 Fax: (608) 785-6910 VERIFICATION OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) provides
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationStudents With Attention Deficit Hyperactivity Disorder
On January 29, 2018 the Arizona State Board of Education approved a list of qualified professionals for identification of educational disabilities as developed by the Arizona Department of Education. Categories
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationIRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING
FOR IMMEDIATE RELEASE IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING George Town, Cayman Islands January 10, 2019 Ironshore
More informationPharmacotherapy of Adult ADHD
Pharmacotherapy of Adult ADHD Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Disclosures Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted
More informationCase Vignettes ANSWER KEY
Case Vignettes ANSWER KEY CASE 1 Cesar, an 8 year old, 38 kg Hispanic boy, presents to your office, transferring care from another PCP across town. He presents with complaints of significant hyperactivity,
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationCase Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources
Case Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources Case 3. Risk of Abuse of ADHD Medications Provider: American Pharmacists Association
More informationADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
More informationScottish Medicines Consortium
Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the
More information